Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07277660 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

Study acronym: PossibILity
StatusActive, Not Recruiting
PhasePhase 2
Started2025-12-29
View on ClinicalTrials.gov ↗

Amendment history

2026-09-23
Enrollment closed, study ongoing
2026-09-10
Study Status, Contacts/Locations v15
Trial sites reduced: 68 → 59 locations
Study sitesdetails revised at 1 of 68 sites
2026-08-26
Study Status, Contacts/Locations v14
Study sitesdetails revised at 58 of 68 sites
2026-08-13
Study Status, Contacts/Locations v13
Study sitesdetails revised at 1 of 68 sites
2026-07-16
Study Status, Contacts/Locations v12
Study sitesdetails revised at 1 of 68 sites
Show 3 earlier versions
2026-07-02
Study Status, Contacts/Locations v11
Study sites66→68
2026-06-18
Study Status, Contacts/Locations v10
Study sites64→66
2026-06-04
Study Status, Contacts/Locations v9
Study sites62→64
2026-05-21
Study Status, Contacts/Locations v8
Trial sites expanded: 57 → 62 locations
2026-05-07
Study Status, Contacts/Locations v7
Trial sites expanded: 50 → 57 locations
2026-04-23
Study Status, Contacts/Locations v6
Trial sites expanded: 23 → 50 locations
2026-03-26
Study Status, Contacts/Locations v5
Study sites21→23
2026-03-12
Study Status, Contacts/Locations v4
Study sites16→21
2026-02-26
Study Status, Contacts/Locations v3
Study sites9→16
2026-02-12
Study Status, Contacts/Locations v2
Study sites7→9
2026-01-27
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2027-05→2027-05-17
Completion date2028-03→2028-03-06
Start dateestimated 2025-12→confirmed 2025-12-29
Study sites0→7
2025-12-02
Original filing
The purpose of the study is to evaluate the dose-response relationship of galvokimig compared with placebo in study participants with moderate-to-severe atopic dermatitis (AtD).
Trial Details
NCT Number NCT07277660
Lead Sponsor UCB Biopharma SRL
Conditions Atopic Dermatitis
Enrollment 165 participants
Start Date 2025-12-29
Primary Completion 2027-05-17 (estimated)
Study Completion 2028-03-06 (estimated)
Updated on ClinicalTrials.gov 2026-09-25